|
|
President's
Message
AMP’s
Training and Education Committee has assembled a program, a
panel discussion, for the Trainee Luncheon at our 2009
Annual Meeting. The proposed theme for the day is “Can you
be ONLY a molecular pathologist ... especially in these
times?” The panel includes representatives of various
practice situations: academic, community hospital, and
industry. All the panel members are distinguished molecular
pathologists.
The
organizers, I think, really want to address whether one can
obtain employment solely in a molecular diagnostics
laboratory, or whether one needs to couple this pursuit with
another pathology skill, e.g., cytology, surgical pathology
or transfusion medicine. The practical import of this for a
trainee, and those who oversee training programs, is that
these considerations influence how one trains in preparation
for that career. There are really two dimensions to the
question. The first deals with the practical skills one
needs to obtain employment in one’s field in an agreeable
setting. Like it or not, the realities of procedural and
professional reimbursement, as well as demands for specific
professional services will largely determine the marketplace
for pathologists with specific skills. The second question
is, to a degree, more philosophical, but still has very
practical ramifications: how does one become a molecular
pathologist or perhaps more to the point, what does it mean
to be a molecular pathologist? I won’t try to guess what
sage advice the luncheon panel will offer for someone
looking to land their first job, but I would like to explore
what it means to be a molecular pathologist in today’s
world.
Of late,
I have been thinking more and more about the model of
medicine, the biopsychosocial model, I was imbued with
during medical training at the University of Rochester.
Most of us practice a biomedical model of medicine: every
disease has an underlying biological/biochemical etiology.
Physio-chemical-genetic abnormalities define the disease.
Our job as pathologists is to detect that abnormality. The
biopsychosocial model, in contrast, is a systems approach
that recognizes that a person’s well being is reflected in
multiple levels of organization: genetic, biochemical,
tissue, organs, organ systems, person, etc. A perturbation
at any one level can be manifest at one or more other
levels, including the psychological and societal. Exploring
this biopsychosocial perspective is valuable for us as
pathologists today in two respects. First is an expanded
concept of “disease” that comes with this model. The
notion of “disease”, certainly in the patient’s mind, is
very much intertwined with the patient’s first interaction
with a clinician. A contract is entered into by both the
patient and the clinician to address the patient’s concern,
and simply the suggestion of an abnormality to explain the
patient’s symptoms can cause considerable angst. Even if
corroborated by a laboratory test result, we need to
acknowledge that acceptance of, and coping with, that result
are part of the disease process. I wonder, then, about
those tests that we propose for asymptomatic patients under
the guise of preventive medicine. Increasingly these are
being offered directly to consumers, with the explanation
that the results are of “no known clinical significance”, or
are intended solely to induce “lifestyle changes”. Is it
possible to perform any test on a healthy asymptomatic
patient without instilling some modicum of anxiety? Is it
conceivable that one can receive news of harboring genetic
changes “of no known clinical significance” and not feel
like damaged goods, or be concerned about the potential
consequences for one’s self or one’s family? Are we
creating “disease” where there is none and conveniently
discounting it because it does not fit our biomedical
model? From this vantage it seems pretty clear that our
responsibilities as the producers of test results go far
beyond the paper the results are written on, indeed well
beyond what we think of as the traditional practice of
pathology. The key point to be made here is that the
diagnosis of disease does not begin or end with a test
result, but travels up and down through the various
biopsychosocial strata.
Secondly,
a systems approach is useful in understanding the breadth of
pathology as a medical discipline. Of necessity, most
medical specialties focus their attention on one or few
levels of organization. Pathologists have traditionally
functioned at the gross anatomic (organs and tissues) and
microscopic level, focusing on tissues and cells, rarely,
often unwittingly, entering the molecular domain through
immunohistochemistry or FISH. Laboratory medicine operates
in the biochemical world. Molecular pathology takes us one
level beyond that into the new realm of molecular genetics,
opening into the parallel dimensions of heredity and
regulation. In exploring this systems approach, what
becomes crystal clear is that none of these organizational
levels are independent, and that those who aspire to be
molecular pathologists really have no choice than to pursue
proficiency in the traditional areas of clinical and
anatomic pathology, and even levels above that, all the way
to the patient himself. Conversely, one cannot espouse to
be an anatomic or clinical pathologist today without also
being a molecular pathologist.
So what
does it mean to be a molecular pathologist? I think it is
clear that molecular pathologists are pathologists1
who have an understanding of disease processes that extends
into the molecular domain. Some of these individuals may
choose to practice as surgical pathologist, others as
hematopathologists, or as microbiologists, or in some other
specialty area but they should all be recognized as
molecular pathologists. It is useful to keep this in mind
while addressing the very practical concern about what
skills one needs to function in this profession, and avoid
defining one’s identity simply by what techniques they use
or what they do. It’s what they know and how they think that
counts.
1
I’m using the term pathologist in its most generic sense,
and consider it to include all engaged in the study of
disease processes. |